Cargando…

No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease

Hemostatic changes and endothelial activations have been recognized in β-thalassemic patients after matched-donor hematopoietic stem cell transplantation (HSCT) but there are limited studies for haploidentical HSCT. This report demonstrates that the levels of hemostatic and endothelial markers, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lertthammakiat, Surapong, Sitthirat, Peerasit, Anurathapan, Usanarat, Songdej, Duantida, Pakakasama, Samart, Chuansumrit, Ampaiwan, Putawornsub, Nattaphat, Sirasittikarn, Sawitt, Wantanawijarn, Sataporn, Kadegasem, Praguywan, Hongeng, Suradej, Sirachainan, Nongnuch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739460/
https://www.ncbi.nlm.nih.gov/pubmed/33327955
http://dx.doi.org/10.1186/s12959-020-00232-z
Descripción
Sumario:Hemostatic changes and endothelial activations have been recognized in β-thalassemic patients after matched-donor hematopoietic stem cell transplantation (HSCT) but there are limited studies for haploidentical HSCT. This report demonstrates that the levels of hemostatic and endothelial markers, including thrombin antithrombin complex, prothrombin fragment, D-dimer, von Willebrand factor antigen and thrombomodulin levels, were not significantly different between haploidentical and matched-donor HSCT patients.